CMS' support for blood pressure procedure a win for Medtronic, say analysts

** Shares of medical device maker Medtronic MDT.N rise 3% to $92.16 premarket

** Late on Thursday, the Centers for Medicare & Medicaid Services released a memosupporting insurance coverage for renal denervation (RDN) procedures, which are used to treat high blood pressure

** Brokerage BTIG says this is a "win" for Medtronic who has been preparing hospitals for coverage with the launch of its Symplicity Spyral renal denervation device

** "We came away encouraged by the proposed coverage for a broader patient population" says brokerage Leerink Partners

** RBC Capitals Markets says this indicates MDT's potential to tap into the vast market, giving them further confidence in the durability of co's revenue growth profile

** Up to last close, stock was up 12% YTD